Skip to content

Evaluation of the analgesic effects of ketamine and fentanyl as an Additive to Intrathecal bupivacaine in patients undergoing cesarean section

Comparison of Postoperative Analgesic Effect of intrathecal ketamine and fentanyl added to bupivacaine in Patients undergoing cesarean section

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12611001109998
Acronym
nil
Enrollment
90
Registered
2011-10-25
Start date
2011-05-15
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Objective :To compare the analgesic effect of intratechal fentanyl and ketamine as an additive to bupivacaine in patients undergoing cesarean section . Methods:Following Ethics Committee approval and informed patients consent, Ninety patients 18-45 yr old ASA physical status I or II, scheduled for cesarean section under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free ,the fentanyl group (groupF) received bupivacaine 10mg combined with 25 microgram fentanyl and the placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally . Time to first requirement of analgesic supplement, Sensory block onset time, maximum sensory level , onset of motor block, duration of blockade, hemodynamics variables, the incidence of hypotension, ephedrine requirements, bradycardia ,hypoxemia [Saturation of peripheral oxygen (SpO2)<90], postoperative analgesic requirements and Adverse events, such as sedation, dizziness , Pruritus and postoperative nausea and vomiting were recorded. Patients were instructed preoperatively in the use of the verbal rating scale (VRS) from 0 to 10 (0no pain, 10maximum imaginable pain) for pain assessment. If the VRS exceeded four and the patient requested a supplement analgesic, diclofenac Na supp 100 mg was to be given for post-operative pain relief as needed . For breakthrough pain(VRS >4) if time of administration of diclofenac Na less than 8h,Pethidine 25 mg IV was given.

Interventions

Ninety patients 18-45 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for cesarean section under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The Ketamin group (group K) received bupivacaine 10 mg combined with0.1mg/kg ketamine preservative free solution ,The fentanyl group (groupF) received bupivacaine 10mg combined with25microgramg fentanyl and Th

Ninety patients 18-45 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for cesarean section under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The Ketamin group (group K) received bupivacaine 10 mg combined with0.1mg/kg ketamine preservative free solution ,The fentanyl group (groupF) received bupivacaine 10mg combined with25microgramg fentanyl and The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)

Sponsors

Qazvin University of Medical Science.
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

patients with American Society of Anesthesiologists(ASA) physical status I and II, undergoing elective cesarean section

Exclusion criteria

significant coexisting disease such as hepato-renal and cardiovascular disease, any contraindication to regional anesthesia such as local infection or bleeding disorders, allergy to ketamine or midazolam , long-term opioid use or a history of chronic pain.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026